The anti-PD-L1 monoclonal antibody (mAb), durvalumab, is being assessed in combination with cetuximab and radiotherapy in locally advanced HNSCC in an ongoing phase I/II trial, including both HPV-positive and HPV-negative subjects (DUCRO; NCT03051906). Here, CD274 is linked to head and neck squamous cell carcinoma.